Lisata Therapeutics (LSTA) Projected to Post Quarterly Earnings on Thursday

Lisata Therapeutics (NASDAQ:LSTA) will likely be issuing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.74) per share for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

Lisata Therapeutics Stock Down 0.2%

Shares of LSTA stock opened at $4.55 on Thursday. The company has a 50 day moving average price of $3.06 and a 200-day moving average price of $2.60. Lisata Therapeutics has a 52 week low of $1.81 and a 52 week high of $4.89. The firm has a market capitalization of $40.13 million, a PE ratio of -2.14 and a beta of 1.25.

Institutional Trading of Lisata Therapeutics

Hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC increased its position in Lisata Therapeutics by 6.1% in the fourth quarter. Renaissance Technologies LLC now owns 123,715 shares of the company’s stock worth $230,000 after buying an additional 7,093 shares in the last quarter. Cerity Partners LLC bought a new position in shares of Lisata Therapeutics during the 2nd quarter valued at approximately $32,000. Finally, CIBC Bancorp USA Inc. purchased a new stake in Lisata Therapeutics in the 3rd quarter worth approximately $37,000. Institutional investors own 8.94% of the company’s stock.

Analyst Upgrades and Downgrades

LSTA has been the subject of a number of research analyst reports. Brookline Capital Acquisition lowered shares of Lisata Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lisata Therapeutics in a report on Thursday, January 22nd. Finally, Zacks Research cut Lisata Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 10th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $23.50.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.